Number of patients with AEs
| . | Imatinib . | Imatinib + Peg–IFN-α2b . | ||
|---|---|---|---|---|
| Any . | Grade 3 or 4 . | Any . | Grade 3 or 4 . | |
| Nonhematologic AE | ||||
| Superficial edema | 7 | 0 | 3 | 0 |
| Nausea | 2 | 0 | 5 | 1 |
| Muscle cramps | 9 | 1 | 3 | 1 |
| Musculoskeletal pain | 3 | 0 | 9 | 3 |
| Rash | 9 | 0 | 15 | 4 |
| Fatigue | 6 | 1 | 13 | 2 |
| Diarrhea | 5 | 1 | 7 | 1 |
| Headache | 1 | 0 | 3 | 0 |
| Abdominal pain | 1 | 0 | 1 | 0 |
| Vomiting | 2 | 1 | 1 | 0 |
| Joint pain | 1 | 0 | 0 | 0 |
| Dyspepsia | 0 | 0 | 1 | 0 |
| Dizziness | 0 | 0 | 1 | 1 |
| Upper respiratory tract infection | 0 | 0 | 3 | 1 |
| Weight gain | 1 | 0 | 1 | 0 |
| Pyrexia | 0 | 0 | 1 | 0 |
| Insomnia | 0 | 0 | 1 | 0 |
| Depression | 2 | 0 | 1 | 0 |
| Other | 11 | 5 | 17 | 4 |
| Hematologic AE | ||||
| Neutropenia | 7 | 7 | 21 | 21 |
| Thrombocytopenia | 1 | 1 | 2 | 2 |
| Biochemical AE | ||||
| ALAT | 1 | 1 | 2 | 2 |
| . | Imatinib . | Imatinib + Peg–IFN-α2b . | ||
|---|---|---|---|---|
| Any . | Grade 3 or 4 . | Any . | Grade 3 or 4 . | |
| Nonhematologic AE | ||||
| Superficial edema | 7 | 0 | 3 | 0 |
| Nausea | 2 | 0 | 5 | 1 |
| Muscle cramps | 9 | 1 | 3 | 1 |
| Musculoskeletal pain | 3 | 0 | 9 | 3 |
| Rash | 9 | 0 | 15 | 4 |
| Fatigue | 6 | 1 | 13 | 2 |
| Diarrhea | 5 | 1 | 7 | 1 |
| Headache | 1 | 0 | 3 | 0 |
| Abdominal pain | 1 | 0 | 1 | 0 |
| Vomiting | 2 | 1 | 1 | 0 |
| Joint pain | 1 | 0 | 0 | 0 |
| Dyspepsia | 0 | 0 | 1 | 0 |
| Dizziness | 0 | 0 | 1 | 1 |
| Upper respiratory tract infection | 0 | 0 | 3 | 1 |
| Weight gain | 1 | 0 | 1 | 0 |
| Pyrexia | 0 | 0 | 1 | 0 |
| Insomnia | 0 | 0 | 1 | 0 |
| Depression | 2 | 0 | 1 | 0 |
| Other | 11 | 5 | 17 | 4 |
| Hematologic AE | ||||
| Neutropenia | 7 | 7 | 21 | 21 |
| Thrombocytopenia | 1 | 1 | 2 | 2 |
| Biochemical AE | ||||
| ALAT | 1 | 1 | 2 | 2 |
n = 56 in each study arm. AEs were recorded during 52 weeks of treatment.
ALAT indicates alanine aminotransferase.